• 1
    Buyon JP, Tamerius J, Belmont HM, Abramson SB: Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Arthritis Rheum 35: 10281037, 1992
  • 2
    Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A: Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312: 15941599, 1985
  • 3
    Senaldi G, Makinde VA, Vergani D, Isenberg DA: Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 47: 913917, 1988
  • 4
    Gawryl MS, Chudwin DS, Langlois PF, Lint TF: The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 31: 188195, 1988
  • 5
    Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S: Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate exacerbations of disease. Arthritis Rheum 29: 10851089, 1986
  • 6
    Hopkins P, Belmont HM, Buyon J, Philips M, Weissman, G, Abramson SB: Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31: 632641, 1988
  • 7
    Porcel JM, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo MJ, Gene T, Warburton F, Kraus M, Vergani D: The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 74: 283288, 1995
  • 8
    Kerr LD, Adelsberg BR, Spiera H: Complement activation in systemic lupus erythematosus: a marker of inflammation. J Rheumatol 13: 313319, 1986
  • 9
    Rother E, Lang B, Coldewey R, Hartung K, Peter HH: Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 12: 3135, 1993
  • 10
    Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, Daha MR, van Es LA: The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 28: 904913, 1985
  • 11
    Schur PH: Complement and lupus erythematosus. Arthritis Rheum 25: 793798, 1982
  • 12
    Penin LH, Lambert PH, Miescher PA: Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 56: 165176, 1975
  • 13
    Nusinow SR, Zuraw BL, Curd JG: Hereditary and acquired deficiencies of complement. Med Clin North Am 69: 487504, 1985
  • 14
    Fielder AHL, Walport MJ, Batchelor JR, Rynes RI, Black CM, Dodi IA, Hughes GRV: Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. BMJ 286: 425428, 1983
  • 15
    Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32: 11071118, 1989
  • 16
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35: 630640, 1992
  • 17
    Liang MH, Socher SA, Roberts WN, Esdaile JM: Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31: 817825, 1988
  • 18
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 12711277, 1982
  • 19
    Pirani CL, Pollak VE: Systemic lupus erythematosus (SLE) glomerulonephritis (lupus nephritis). In, Immunologically Mediated Renal Disease. Edited by RTMcCluskey, GAAndres. New York, Marcel Dekker, 1978
  • 20
    Tack BF, Janatova J, Thomas ML, Harrison RA, Hammer CH: The third, fourth and fifth components of human complement: isolation and biochemical properties. Methods Enzymol 80: 9091, 1981
  • 21
    Schreiver H, Gambino SR: Protein turbidity produced by trichlo-roacetic acid and sulfosalicylic acid at varying temperatures and varying ratios of albumin and globulin. Am J Clin Pathol 44: 667672, 1965
  • 22
    Kelly RH, Vertosick FT: Electrophoretic analysis of proteins. In, Manual of Clinical Laboratory Immunology. Fourth edition. Edited by NRRose, HFriedman, JLFahey. Washington, DC, American Society of Microbiology, 1992
  • 23
    Kelly RH, Carpenter AB, Sudol KS, Jagarlapudi SP, Manzi S: Complement C3 fragments in urine: detection in systemic lupus erythematosus patients by Western blotting. Appl Theor Electrophor 3: 265269, 1993
  • 24
    Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8: 283298, 1978
  • 25
    Craemer HC: Assessment of 2×2 associations: generalization of signal-detection methodology. Am Statistician 42: 3749, 1988
  • 26
    Stachura I, Ellis D, Kelly RH: Urinary immune complexes in patients with glomerular diseases. Arch Pathol Lab Med 107: 315318, 1983
  • 27
    Abramson SB, Weissmann G: Complement split products and pathogenesis of SLE. Hosp Pract 15: 4556, 1988
  • 28
    Abramson SB, Belmont HM, Hopkins P, Buyon J, Winchester R, Weissmann G: Complement activation and vascular injury in systemic lupus erythematosus. J Rheumatol 14: 4346, 1987
  • 29
    Seifter S, Eckert EE: Complement and isohemagglutinins in urinary proteins. J Clin Invest 25: 809813, 1946
  • 30
    Peakman M, Lobo-Yeo A, Senaldi G, Nilsson M, Tee DEH, Vergani D: Quantification of C3d in biological fluids by an enzyme-linked immunosorbent assay. J Immunol Methods 104: 5156, 1987
  • 31
    Lange K, Wenk EJ: Complement components in the sera and urines of patients with severe proteinuria. Am J Med Sci 228: 448453, 1954
  • 32
    Sanders ME, Alexander EL, Koski CL, Frank MM, Joiner KA: Detection of activated terminal complement (C5b-9) in cerebro-spinal fluid from patients with central nervous system involvement of primary Sjögren's syndrome or systemic lupus erythematosus. J Immunol 138: 20952099, 1987
  • 33
    Lund ED, Sorensen LS, Brandslund I: Specificities of monoclonal antibodies against the complement C3d split product. Complement Inflamm 7: 1829, 1990
  • 34
    Hemmingsen L, Skaarup P: The 24-hour excretion of plasma proteins in urine of apparently healthy subjects. Scand J Clin Lab Invest 35: 347353, 1975
  • 35
    Muso E, Sekita K, Doi T, Kuwahara T, Yoshida H, Tamura T, Kawai C, Hamashima Y: Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis. Clin Immunol Immunopathol 32: 351358, 1984
  • 36
    Gado K, Robinson M, Bacon PC, Emery P: C3d estimation in patients with vasculitis: evidence for in vivo complement activation and correlation with disease activity (abstract). Br J Rheumatol 30 (Suppl 1): 18, 1991
  • 37
    Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB: Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 35: 5561, 1992